Q-omics provides the consensus-scored FAM171B profile across patient tissues and cancer cell-line models. FAM171B expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM171B is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, FAM171B RNA expression shows 19,253 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, BLCA, and UVM as cancer lineages where FAM171B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM171B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM171B survival associations across molecular data types. FAM171B RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM171B RNA expression–survival associations across cancer types. High FAM171B expression shows unfavorable associations in KIRP, BLCA, UVM, STAD and CESC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM171B RNA expression.
This table summarizes FAM171B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM171B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM171B shows lower tumor expression in KICH and higher tumor expression in BLCA, LIHC, LUAD, CHOL and LUSC. The BLCA box plot shows higher FAM171B RNA expression in tumor versus normal tissue (log2 FC = +1.036, t-test p < 0.001).
This table shows molecular features associated with FAM171B in patient tissues and cancer cell lines. In patient samples, FAM171B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM171B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
